Extrait

Phase I part: - To assess the MTDs and the dose-limiting toxicities (DLTs) for each dosing schedule tested. - To determine the optimal dosing schedule and its associated recommended Phase II dose. Phase II part: - To assess the objective response rate at the recommended dose of the optimal dosing schedule defined in the phase I part.

Critère d'inclusion

• Hodgkin's disease (HD) , non-Hodgkin lymphoma (NHL) and chronic lymphocytic Leukaemia (CLL)

Liens

• ictrp
• ictrp
• ictrp
• euctr
• euctr
• euctr
• euctr
• ictrp